ImmuCell Corporation (ICCC)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in ImmuCell Corporation, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

ImmuCell Corporation (ICCC) has returned 2.93% so far this year and 32.15% over the past 12 months. Over the last ten years, ICCC has returned -0.34% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Jul 10, 1995, ICCC's average daily return is +0.13%, while the average monthly return is +1.39%. At this rate, your investment would double in approximately 4.2 years.

Historically, 49% of months were positive and 51% were negative. The best month was Mar 1996 with a return of +80.0%, while the worst month was Mar 2020 at -34.1%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 9 months.

On a daily basis, ICCC closed higher 41% of trading days. The best single day was Feb 8, 2000 with a return of +127.3%, while the worst single day was Feb 9, 2000 at -28.5%.

ImmuCell Corporation has an annualized alpha of 34.23%, beta of 0.37, and R² of 0.01 versus S&P 500 Index. Calculated based on daily prices since July 11, 1995.

• This stock participated in 55.73% of S&P 500 Index downside but only 44.13% of its upside — more exposed to losses than it benefited from rallies.
• Beta of 0.37 may look defensive, but with R² of 0.01 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.01 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ICCC ranks 58 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for ImmuCell Corporation (ICCC) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the ImmuCell Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the ImmuCell Corporation was 85.30%, occurring on Feb 27, 2009. Recovery took 1615 trading sessions.

The current ImmuCell Corporation drawdown is 46.72%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of ImmuCell Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how ImmuCell Corporation is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.